Roger Gomis

Institut de Recerca Biomèdica de Barcelona

Life & Medical Sciences

Dr. Roger Gomis is an ICREA Research Professor and a member of the Oncology Program at the Institute for Research in Biomedicine, Barcelona. He received his PhD in biochemistry from the University of Barcelona in 2002, and was a postdoctoral fellow at Memorial Sloan-Kettering Cancer Center in Prof. Joan Massagué's laboratory. In 2007, he assumed his current position. Dr. Roger Gomis is interested in how growth factors, signaling pathways, and gene expression programs control normal cell behavior and cancer cell metastasis. Driven by his interest in the problem of metastasis, which is the cause of 90% of cancer deaths, his laboratory is pursuing the molecular and genetic mechanisms of metastasis. In particular, the team focuses on identifying and functionally validating genes that enable cancer to metastasize clinically relevant sites. In 2012 Roger founded Inbiomotion as an ICREA and IRB Barcelona spin-off company from his laboratory research.

Research interests

Intricate signalling networks control cell division, differentiation, movement, organization and death. Cancer cells disobey these signals during tumour progression and metastasis, which is the final step in 90% of all fatal solid tumours. Metastasis is therefore a grave public health problem and consequently a field of considerable pharmaceutical interest. A major research focus of our group is to identify and understand the genes and functions that allow tumor cells to achieve metastatic colonization of vital organs. As we understand more about the biology of BC cells, we can begin to address how best to treat this form of disease. Key to determining whether dormant solitary cells or micrometastases represent valid targets is knowledge of the underlying biology of dormancy and the probability of cells progressing to active metastatic growth. This progression is poorly understood in preclinical models and even less so clinically and has become of our interest.

Selected publications

- Coleman RE, Collinson M, Gregory W, Marshall H, Bell R, Dodwell D, Keane M, Gil M, Barrett-Lee P, Ritchie D, Bowman A, Liversedge V, De Boer RH, Passos-Coelho JL, O'Reilly S, Bertelli G, Joffe J, Brown JE, Wilson C, Tercero JC, Jean-Mairet J, Gomis R & Cameron D 2018, 'Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)' Journal of Bone Oncology Vol.13 pp:123-135.

- Gawrzak S, Rinaldi L, Gregorio S, Arenas EJ, Salvador F, Urosevic J, Figueras-Puig C, Rojo F, del Barco Barrantes I, Miguel Cejalvo J, Palafox M, Guiu M, Berenguer-Llergo A, Symeonidi A, Bellmunt A, Kalafatovic D, Arnal-Estape A, Fernandez E, Mullauer B, Groeneveld R, Slobodnyuk K, Stephan-Otto Attolini C, Saura C, Arribas J, Cortes J, Rovira A, Munoz M, Lluch A, Serra V, Albanell J, Prat A, Nebreda ARAznar Benitah S & Gomis RR 2018, 'MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer', Nat Cell Biol, 20, 211 - 221.

- Salvador F & Gomis RR 2018, 'Paraspeckle factor turns TGF-β1 pro-metastatic'. Nat Cell Biol. 20: 367-369.   

- Salvador F & Gomis RR 2018, 'CLK2 blockade modulates alternative splicing compromising MYC-driven breast tumors', EMBO Mol Med. pii: e9213.

- Canovas B, Igea A, Sartori AA, Gomis RR, Paull TT, Isoda M, Perez-Montoyo H, Serra V, Gonzalez-Suarez E, Stracker TH & Nebreda AR  2018, 'Targeting p38 alpha Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells', Cancer Cell, 33, 6, 1094.

- Cortazar AR, Torrano V, Martín-Martín N, Caro-Maldonado A, Camacho L, Hermanova I, Guruceaga E, Lorenzo-Martín LF, Caloto R, Gomis RR, Apaolaza I, Quesada V, Trka J, Gomez-Muñoz A, Vicent S, Bustelo XR, Planes FJ, Aransay AM, Carracedo A. 2018, 'CANCERTOOL: a visualization and representation interface to exploit cancer datasets',  Cancer Res., 78, 21, 6320 - 6328.1669.